A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) - Trial NCT03175120
Access comprehensive clinical trial information for NCT03175120 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 453 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novo Nordisk A/S
Timeline & Enrollment
Phase 3
May 26, 2017
Apr 04, 2019
Primary Outcome
Change in HbA1c
Summary
This trial is conducted in Asia. The aim of this trial is to confirm the superiority of
 insulin degludec/liraglutide versus insulin degludec in controlling glycaemia in Chinese
 subjects with type 2 diabetes mellitus after 26 weeks of treatment
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03175120
Non-Device Trial